Please provide your email address to receive an email when new articles are posted on . The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third ...
The company’s product releases cell therapy into the eye via injection to slow down vision loss Clinical-stage biotech company jCyte Inc. is developing its cell therapy treatment jCell for retinitis ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 ...
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback